These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1348429)

  • 1. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?
    Lawlor BA; Davis KL
    Biol Psychiatry; 1992 Feb; 31(4):337-50. PubMed ID: 1348429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate transmission and toxicity in Alzheimer's disease.
    Greenamyre JT; Maragos WF; Albin RL; Penney JB; Young AB
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):421-30. PubMed ID: 2900537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate in the mammalian CNS.
    Sahai S
    Eur Arch Psychiatry Clin Neurosci; 1990; 240(2):121-33. PubMed ID: 1981150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease.
    Cowburn R; Hardy J; Roberts P; Briggs R
    Neurosci Lett; 1988 Mar; 86(1):109-13. PubMed ID: 2896322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM
    Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glutamatergic system and Alzheimer's disease: therapeutic implications.
    Butterfield DA; Pocernich CB
    CNS Drugs; 2003; 17(9):641-52. PubMed ID: 12828500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
    Farlow MR
    Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-methyl-D-aspartate receptors and Alzheimer's disease.
    Cotman CW; Geddes JW; Bridges RJ; Monaghan DT
    Neurobiol Aging; 1989; 10(5):603-5; discussion 618-20. PubMed ID: 2572983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track?
    Esposito Z; Belli L; Toniolo S; Sancesario G; Bianconi C; Martorana A
    CNS Neurosci Ther; 2013 Aug; 19(8):549-55. PubMed ID: 23593992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.
    Wenk GL; Parsons CG; Danysz W
    Behav Pharmacol; 2006 Sep; 17(5-6):411-24. PubMed ID: 16940762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.
    Doraiswamy PM
    Curr Neurol Neurosci Rep; 2003 Sep; 3(5):373-8. PubMed ID: 12914679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectivity of excitotoxic mechanisms in Alzheimer's disease.
    May PC
    Neurobiol Aging; 1989; 10(5):606-8; discussion 618-20. PubMed ID: 2572984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Glutamate and NMDA Receptors in Alzheimer's Disease.
    Wang R; Reddy PH
    J Alzheimers Dis; 2017; 57(4):1041-1048. PubMed ID: 27662322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG; Stöffler A; Danysz W
    Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate-glutamine cycling in Alzheimer's disease.
    Walton HS; Dodd PR
    Neurochem Int; 2007 Jun; 50(7-8):1052-66. PubMed ID: 17141374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders.
    Louzada PR; Paula Lima AC; Mendonca-Silva DL; Noël F; De Mello FG; Ferreira ST
    FASEB J; 2004 Mar; 18(3):511-8. PubMed ID: 15003996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bench to bedside: the glutamate connection.
    Choi DW
    Science; 1992 Oct; 258(5080):241-3. PubMed ID: 1357748
    [No Abstract]   [Full Text] [Related]  

  • 20. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
    Koutsilieri E; Riederer P
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.